Ozempic Price Comparison
Compare Semaglutide, Wegovy and Rybelsus prices across Clicks, Dis-Chem, Medirite and other South African pharmacies side-by-side — so you never overpay for your prescription.
| Compare | Supplier | Price | Price / mg | Stock | Delivery | Quality | Visit |
|---|
Price/mg is calculated from each product's total active ingredient across a standard 4-dose, 28-day supply, so you can compare cost-efficiency across doses as well as pharmacies.
What Semaglutide Actually Is
The active ingredient inside every Ozempic, Wegovy and Rybelsus pack, explained without the jargon.
Overview
Semaglutide is a long-acting GLP-1 receptor agonist, registered with SAHPRA and sold in South Africa under three separate brand names — Ozempic, Wegovy and, once its commercial launch lands, Rybelsus. It's built from a lab-modified copy of a natural gut hormone, engineered to stay active in the bloodstream for about a week instead of a few minutes, which is what makes once-weekly dosing possible in the first place.
Because the three brands share one molecule but different registered uses, dose ranges and prices, "semaglutide" isn't a single product you can simply ask for at the counter. See our full brand comparison for exactly how Ozempic, Wegovy and Rybelsus differ.
Mechanism of Action
Semaglutide mimics GLP-1, a hormone your gut releases naturally after eating. It binds to GLP-1 receptors to trigger insulin release only when blood sugar is high, dial down glucagon (a hormone that raises blood sugar), slow how quickly food leaves your stomach, and signal fullness to appetite centres in the brain. That combination is what drives both its blood-sugar-lowering effect in diabetes and the appetite-suppressing effect used for weight management.
Key Benefits
- Clinically documented blood sugar control for type 2 diabetes, the basis of Ozempic's registration
- Established cardiovascular risk reduction in patients with type 2 diabetes and existing heart disease
- Significant, sustained weight loss demonstrated in dedicated obesity trials underpinning Wegovy
- Once-weekly injectable dosing, with a once-daily oral tablet option (Rybelsus) in the pipeline for South Africa
- Safety profile backed by tens of thousands of clinical trial participants across more than a decade of study
Quick Stats
The Molecule Behind the Pen
Why a once-a-week injection is even possible.
Amino Acid Sequence
Semaglutide's backbone is a modified version of human GLP-1(7-37), carrying two deliberate changes that give it its week-long half-life: a non-natural amino acid at position 2 that blocks the enzyme which would otherwise break the hormone down within minutes, and a fatty-acid side chain at position 20 that lets it latch onto albumin in the blood.
Modifications
Two changes separate semaglutide from natural human GLP-1: the amino acid at position 2 is swapped for aminoisobutyric acid (Aib), blocking the DPP-4 enzyme that would otherwise break the hormone down within minutes, and the lysine at position 20 carries a C18 fatty diacid chain, attached via a short linker, letting the molecule bind reversibly to albumin in the blood and release slowly over about a week.
None of this changes how you use the pen day to day, but it explains a few things patients often ask about: why the effect builds gradually over the first few weeks rather than kicking in immediately, why missing a dose by a day or two rarely matters much, and why stopping treatment doesn't cause an abrupt rebound the way some faster-acting medicines do.
What Ozempic Is Registered For in South Africa
SAHPRA's approved use, and where off-label prescribing comes in.
The indications below reflect what SAHPRA has actually approved each semaglutide brand to treat in South Africa — not marketing claims. This is general information, not medical advice; only a registered healthcare professional can advise whether any of it applies to you.
Glycaemic Control in Type 2 Diabetes
SAHPRA Approved · OzempicRegistered as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes, either on its own or alongside other diabetes medicines such as metformin.
Cardiovascular Risk Reduction
SAHPRA Approved · OzempicIn adults with type 2 diabetes and established cardiovascular disease, Ozempic is registered to reduce the risk of major adverse cardiovascular events — heart attack, stroke and cardiovascular death.
Chronic Weight Management
SAHPRA Approved · WegovyWegovy is registered specifically for long-term weight management in adults with obesity, or overweight with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.
Weight Loss (Off-Label Use of Ozempic)
Off-Label · Doctor's DiscretionMany South African doctors prescribe Ozempic off-label for weight loss at a patient's request, but that isn't what Ozempic is registered for — Wegovy is the SAHPRA-approved option built and dosed specifically for that purpose.
If weight loss is your main goal, ask your doctor whether Wegovy — or eventually Rybelsus — is the better-registered fit than an off-label prescription. See our full brand comparison for how the three stack up.
Dosing Protocols
How semaglutide is actually dosed in South Africa, by format — always follow your own prescription over a general guide.
Injectable — Ozempic & Wegovy
Pre-filled pen devices for once-weekly subcutaneous injection. Ozempic is dosed for diabetes management and cardiovascular risk reduction; Wegovy is dosed higher, specifically for chronic weight management.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Diabetes initiation (Ozempic) | 0.25 mg | Weekly × 4 weeks, then increase | Subcutaneous |
| Diabetes maintenance (Ozempic) | 0.5 mg – 1 mg | Weekly | Subcutaneous |
| Extended diabetes control (Ozempic) | 2 mg | Weekly, where prescribed | Subcutaneous |
| Cardiovascular risk reduction (Ozempic) | 0.5 mg – 1 mg | Weekly | Subcutaneous |
| Weight management initiation (Wegovy) | 0.25 mg | Weekly × 4 weeks, then increase | Subcutaneous |
| Weight management maintenance (Wegovy) | 2.4 mg | Weekly, after ~16-week titration | Subcutaneous |
Key Tips
- Once-weekly dosing, ideally the same day every week
- Injected into the abdomen, thigh or upper arm — rotate sites to reduce irritation
- Pre-filled, ready-to-use pens — no mixing or reconstitution required
- Each step up in dose typically happens no sooner than four weeks apart, to let your body adjust
Oral — Rybelsus (Not Yet Available in SA)
Rybelsus tablets use SNAC absorption-enhancing technology so semaglutide survives the digestive tract. SAHPRA registered it in 2024, but it hasn't yet reached South African pharmacy shelves commercially.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Diabetes initiation | 3 mg | Daily × 30 days | Oral, empty stomach |
| Standard diabetes dose | 7 mg | Once daily | Oral, empty stomach |
| Maximum diabetes dose | 14 mg | Once daily | Oral, empty stomach |
Key Tips
- No injection required — a once-daily tablet instead
- Take first thing in the morning, on an empty stomach, with no more than half a glass of plain water
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines
- Swallow whole — do not split, crush or chew the tablet
Safety Information Worth Knowing Before You Start
General safety information only — not a substitute for the package insert or your doctor's guidance.
💊 Common Side Effects
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Abdominal discomfort
🩺 Monitoring
- Blood glucose levels
- Signs of pancreatitis
- Thyroid symptoms
- Kidney function
⚠️ Stop Signs — Get Help Urgently
- Severe or persistent abdominal pain (possible pancreatitis)
- Persistent vomiting preventing fluid intake
- Neck lump, hoarseness or trouble swallowing (possible thyroid issue)
- Severe allergic reaction — rash, itching, difficulty breathing
- Severe hypoglycaemia, especially if combined with insulin or sulfonylureas
🚫 Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or breastfeeding
- History of pancreatitis
Quality Checklist
What to look for — and what to run from — before you inject anything.
✅ Good Signs
- SAHPRA-registered branded product (Ozempic or Wegovy) dispensed by a licensed pharmacy
- Proper cold-chain storage, with a valid batch number and expiry date
- Clear, colourless to slightly yellow solution inside the pen
⚠️ Warning Signs
- Compounded or "custom-mixed" semaglutide — SAHPRA has specifically warned the public about unregistered compounded GLP-1 products
🚫 Bad Signs
- Cloudy or discoloured solution, or visible particles
- Dispensed without ever asking for a valid prescription
- Non-pharmacy sources or unverified online sellers
For a deeper look at how registered generics differ from unsafe compounded products, see our generic semaglutide guide, or the full buying safety guide for step-by-step sourcing advice.
The Clinical Evidence Behind Semaglutide
A short summary of the published trials semaglutide's approvals are built on.
Weight management, ~1,961 participants
Adults with obesity (or overweight with a weight-related condition) lost an average of 14.9% of body weight on 2.4mg weekly semaglutide over 68 weeks, versus 2.4% on placebo — the trial underpinning Wegovy's weight-management approval.
Type 2 diabetes, multiple trials
A series of randomised trials in people with type 2 diabetes showed HbA1c reductions of roughly 1.5–1.8 percentage points on semaglutide, forming the core evidence behind Ozempic's diabetes registration.
Oral semaglutide, ~9,500 participants
A programme of trials testing oral semaglutide — the basis for Rybelsus — found blood-sugar control broadly comparable to injectable therapy, the evidence base Rybelsus will lean on once it reaches South African pharmacies.
Cardiovascular outcomes, ~17,600 participants
In adults with existing cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4mg reduced major adverse cardiovascular events by around 20% versus placebo over roughly three years — evidence now reflected in Ozempic's cardiovascular-risk-reduction registration for patients with diabetes and heart disease.
Figures above summarise publicly published trial results for general education and are not a substitute for the official South African package insert, which remains the authoritative source on registered indications and dosing. Always discuss what the evidence means for your own treatment with your doctor.
Ozempic vs Wegovy vs Rybelsus
All three brands use the same active ingredient — semaglutide — but differ in approved use, dose range and availability in South Africa.
Ozempic®
Registered for type 2 diabetes management. The only semaglutide brand widely available in SA pharmacies today. Injectable pen, once weekly.
Wegovy®
Higher-dose semaglutide registered specifically for chronic weight management. Launched in SA in August 2025, with a major price cut in March 2026.
Rybelsus®
The oral (tablet) form of semaglutide. Registered with SAHPRA in 2024 but not yet commercially available for sale in South Africa.
Pharmacies We Track
We monitor pricing across South Africa's largest retail pharmacy chains and reputable telehealth providers.
